Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.
about
STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic InflammationRequirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation.PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33.PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell functionPARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymeraseTherapeutic applications of PARP inhibitors: anticancer therapy and beyondPotential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity.Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy Antigen Receptor for Chemokines.High-fat diet induces lung remodeling in ApoE-deficient mice: an association with an increase in circulatory and lung inflammatory factors.Poly-ADP-ribosyl polymerase-14 promotes T helper 17 and follicular T helper development.Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4⁺ T-cell function without causing severe combined immunodeficiency.PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.PARP-1: a new player in the asthma field?
P2860
Q26738332-344C3EA1-00D1-4076-8FD6-2BE53A8E40D1Q34796204-3795EB66-9F11-4ABD-A216-183116B19B05Q35148141-B757A2FE-D951-4242-9991-8562E9A9D4DEQ35287136-B8D3A2E1-CFEF-4D18-9254-FD399D818E3EQ35810246-530F8D20-51B7-4B6D-81D1-E87B6ED067B3Q35848889-0C4E06A2-0B63-44E5-B9A1-64F3C5370762Q36184688-723F75C6-CCD7-41E2-B7AB-8C14A672EEA7Q36543658-4E748B6E-571B-43CD-B196-BF4CA3104C74Q36853236-9776A67C-7616-45E0-BA9D-AC018D232E41Q37147485-757E722B-2211-4AA4-8B73-DED2DE54F408Q37429317-6DB1F88C-31AB-48DF-96D6-80B802E495C0Q37441933-32513DAD-B9F4-40A9-AEB9-19412732A8BBQ41535001-9046E6F5-43DA-4265-9FF2-D0BA18479B08Q41820940-F97AF3F9-8114-4754-AD4E-26110DD8161DQ43142166-72E72CD7-EDD2-4C01-8323-4AF3138EB4B6Q45340890-1461EFA6-972B-4970-A1C0-176FFBF45443Q51529685-4E0F5640-1FD3-4996-9302-D3C4C1A0CAE1Q52372449-30CA6A89-415A-4E6F-AFC2-E14E69B066B1Q53830448-E4EF4C36-1202-4B39-8C87-28E5A9FDD79B
P2860
Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Post-allergen challenge inhibition of poly
@nl
Post-allergen challenge inhibi ...... allergic airway inflammation.
@en
type
label
Post-allergen challenge inhibition of poly
@nl
Post-allergen challenge inhibi ...... allergic airway inflammation.
@en
prefLabel
Post-allergen challenge inhibition of poly
@nl
Post-allergen challenge inhibi ...... allergic airway inflammation.
@en
P2093
P2860
P1476
Post-allergen challenge inhibi ...... allergic airway inflammation.
@en
P2093
A H Boulares
M Zerfaoui
S A Cormier
P2860
P304
P356
10.1111/J.1365-2222.2008.02943.X
P577
2008-02-04T00:00:00Z